Roche and Qualcomm Incorporated’s subsidiary, Qualcomm Life, Inc., a provider of point-of-care diagnostics, have entered into a strategic collaboration to improve remote monitoring and management of chronic-disease patients. The companies aim to advance chronic-care management using connected therapy to further improve therapy quality, increase convenience, and drive patients’ engagement in managing their health.

Under the agreement, Roche will use Qualcomm Life's 2net platform to capture data from a patient's medical devices, beginning with anticoagulation meters, and transmit it to Roche's cloud-based back-end services. The 2net Platform is a secure wireless solution that provides a way to exchange relevant health information between chronic-disease patients and their care team or clinic to enable reduced therapy complications and total cost of care.

Earlier this year, Novartis Pharmaceuticals formed a joint investment company with Qualcomm Ventures, the investment arm of Qualcomm, to target early-stage companies that offer technologies, products, or services to support digital or mobile technologies, such as telephone- enabled devices, mobile applications, wearable devices, and other technologies for big and small data.

Source: Roche